1. Introduction {#sec1}
===============

The annual incidence of *BCR-/ABL1*-negative myeloproliferative neoplasms (MPN), namely polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) in the western world, is estimated to be maximum 2.8, 2.3, and 1.5 cases per 100.000 population, respectively \[[@B1], [@B2]\]. On the other hand, the cumulative incidence of lymphoproliferative disorders (LPD) is difficult to be estimated as they comprise a highly heterogenous group; however, that of a major representative of this group, B-chronic lymphocytic leukemia (B-CLL) seems to be around 5.5 cases per 100.000 population per year \[[@B3]\]. Based on the notion that the concomitance of MPN and LPD in the same patient should be the product of the individual incidence rates, an extremely low incidence of cases with both MPN and LPD would be expected. However, it has been shown that the presence of an MPN increases the probability of an LPD in the same individual. In a study by Vannucchi et al., which included 820 *BCR-/ABL1*-negative MPN patients in a period from 1980 to 2008, 11 concomitant LPD cases were reported, with a 3.44-fold increase in the risk of developing LPD in the MPN group compared with the general population \[[@B4]\]. In addition, Rumi et al. reported 22 concomitant LPD cases in a cohort of 1915 BCR-/ABL1-negative MPN patients followed up from 1970 to 2009, with a 2.79-fold increased risk, respectively \[[@B5]\].

Despite these observations, the coexistence of MPN and LPD remains rather rare; in fact, scarce case reports and limited cases series have been reported \[[@B6]--[@B11]\]. A recent systematic review of single patient clinical data by Marchetti et al. has identified 214 individuals harboring both diseases \[[@B12]\], while a Danish registry reported 97 new LPD cases in patients previously diagnosed with MPN \[[@B13]\].

Herein, we present our institution\'s experience with patients harboring both MPN and LPD, focusing on the peculiarities of their management. Furthermore, we suggest pathophysiological mechanisms that might explain the aforementioned coexistence.

2. Materials and Methods {#sec2}
========================

A thorough search of the records of the Hematology Division of the Second Department of Internal Medicine and Research Institute at Attikon University General Hospital of Athens, Greece, was performed. The search included the records of all patients referred to our institution in the time period from 2003 to 2018. Clinical notes were used to identify patients harboring both diseases. Patient demographics, medical history, initial disorder at presentation, treatment for both diseases, and response to treatment were obtained from patient records. An informed consent was obtained from every subject.

3. Results {#sec3}
==========

The search yielded nine cases of coexistent MPN and LPD out of a total of 269 patients diagnosed with *BCR-/ABL1*-negative MPN (244) or an MDS/MPN (myelodysplastic syndrome/myeloproliferative neoplasms (25)) and 1062 patients diagnosed with an LPD. Patient characteristics are depicted in [Table 1](#tab1){ref-type="table"}.

Six out of the nine patients presented with a *BCR-/ABL1*-negative MPN. More specifically, one patient was diagnosed with PV, one patient with post-ET MF, two patients with primary myelofibrosis (PMF), and the remaining two with pre-fibrotic PMF; all of them were positive for the mutation *JAK2 V617F*. Of these patients, four required treatment with a cytoreductive agent, namely hydroxycarbamide (two of whom also required occasional bloodlettings), whereas one patient (Patient 8) received a JAK2 inhibitor (ruxolitinib) for 7 months. All MPN-treated patients had good control of their symptoms and blood counts.

Three out of the nine patients (patients 3, 6, and 7) were initially diagnosed as MDS-RS-T and were later found to fulfill criteria for MDS/MPN-RS-T according to the 2016 WHO revision \[[@B1]\]. None of them harbored the *JAK2 V617F*mutation; calreticulin (*CALR*) and *MPL W515* mutation studies were negative in Patient 6 but were not performed for patients 3 and 7 due to reimbursement issues. All of them were supported with an erythropoietin analogue and red blood cell transfusions.

Regarding the specific LPD phenotype, variability was noted as three patients were diagnosed with B-CLL and one patient with monoclonal B-cell lymphocytosis (MBL), three patients with lymphoma (two marginal zone lymphomas (MZL) and a plasmablastic lymphoma), and two patients with plasmacytic neoplasms (one with multiple myeloma and one with light and heavy chain deposition disease). All but two of the patients required treatment and were managed appropriately. The exact treatment approach for each patient is depicted in [Table 1](#tab1){ref-type="table"}. Response was defined using the Cheson criteria \[[@B14]\] for patients 4 and 6. These criteria could not be applied for Patient 8 because even though lymphocytosis subsided with treatment, splenomegaly remained due to the underlying MPN. The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria \[[@B15]\] were used for patients 2 and 7. For Patient 9, the response was evaluated based on clinical criteria as discussed below.

All but one patient had significant comorbidities ([Table 1](#tab1){ref-type="table"}). In the two patients with treatment intolerance, exacerbation of anemia was the main cause for stopping treatment. Both patients were old and frail. Patient 7 had been supported with RBC transfusions and erythropoiesis-stimulating agents for her MDS/MPN-RS-T. She only received 2 cycles of obinutuzumab/chlorambucil due to a dramatic increase in her transfusion needs. Her lymphocytosis has been in regression ever since. Patient 5 initially received hydroxycarbamide to control her thrombocytosis, but after 2 years, she developed anemia attributed to myeloma. A trial of lenalidomide was performed, which resulted in transfusion dependency, so treatment was stopped prematurely after a few days. On the other hand, the underlying MDS/MPN-RS-T did not seem to adversely affect treatment outcome of Patient 6, a fitter patient, who received 6 cycles of bortezomib/CHOP, resulting in an astonishing relapse-free survival, as previously reported \[[@B16]\].

It should be noted that the diagnosis of the MPN preceded that of LPD in all patients with the exception of Patient 4. Regarding this patient, a splenic MZL was diagnosed in another institution based on spleen pathology, and at this time point, bone marrow biopsy was reported to be normal and no further information was available in his records. Ten years later, the patient was referred to our institution for a massive abdominal lymphoid block which proved to be a relapse of the original low-grade LPD and for which he was treated with 8 cycles of rituximab. Myelofibrosis and *JAK2 V627* mutation were discovered during restaging of the patient. A few months later, a steady hemoglobin increase was observed and the patient was treated with hydroxycarbamide and phlebotomies. Whether this was a manifestation of his MPN is not known, as the patient (a heavy smoker) was also diagnosed with lung cancer shortly thereafter.

Patient 8 had suffered from ankylosing spondylitis the past 20 years and had received tumor necrosis factors (anti-TNF) to control her symptoms. She also received ruxolitinib for 7 months due to symptomatic splenomegaly. Baseline clonal immunoglobulin gene rearrangements and flow cytometry were not available for this patient before the initiation of ruxolitinib. She gradually developed anemia and clonal B-cell lymphocytosis. After 6 cycles of RCOP, both these findings have subsided. Ruxolitinib was not reintroduced for fear of LPD reoccurrence, as discussed below. Patient 2 received 6 cycles of obinutuzumab/chlorambucil and is currently on CR for his LPD.

Of special consideration is also Patient 9. This patient, having a 4-year history of JAK2-positive post-ET MF, developed persistent diarrheas and acute renal failure. Her serum protein electrophoresis and immunofixation were normal, and her bone marrow exhibited no plasmacytic infiltration. However, renal biopsy showed deposition of monoclonal immunoglobulin (IgAk), establishing the diagnosis of light chain and heavy chain deposition disease (LHCDD), also known as Randall disease, an entity recently recognized in the latest WHO classification \[[@B1]\]. Both diarrhea and acute renal failure subsided after six courses of bortezomib, cyclophosphamide, and dexamethasone. A repeat renal biopsy was not performed.

4. Discussion {#sec4}
=============

We have presented a case series of patients with diverse MPN with or without myelodysplastic features coexisting with various LPD. To our knowledge, it is the first time that a patient with MPN and concomitant LHCDD has been reported. In our study, 3 MDS/MPN-RS-T patients with concomitant LPD are reported, explaining in part the relatively high prevalence of MPN/LPD in our population. Interestingly, there is a paucity of publications regarding the concomitance of MDS/MPN-RS-T with LPD, which suggests that MDS/MPN-RS-T might have been overlooked in previous studies.

Various points should be stressed regarding diagnosis and treatment of patients harboring both a MPN and a LPD. Regarding diagnosis, the presence of the *JAK2 V617F* mutation accompanied by flow cytometry-established B-cell clonality raises suspicion of coexistence of MPN and LPD. However, in *JAK2 V617F*-negative cases, a strict adherence to the WHO criteria for MPN, based on clinicopathological and molecular findings, is required.

The choice of treatment of one disease over the other is challenging. From a clinical point of view, it is often difficult to attribute features such as anemia, splenomegaly, or catabolic symptoms solely to one of the two entities. In such cases, the selection of treatment is guided by the assumed most symptomatic disease and further justified or not by the treatment outcome. In addition, and most importantly, treatment may be complicated by increased intolerance as reported for some of our patients. It has been shown that treatment of LPD may be poorly tolerated in patients with an underlying MPN. This is particularly true for cases with PMF or MDS/MPN overlap syndrome, who often present with anemia. In these cases, treatment of LPD could lead to an exacerbation of anemia due to decreased bone marrow reserve. Poor information is provided in the literature about treatment options and outcome of similar cases with coexistence of myeloid and lymphoid neoplasms. With the increasing awareness of the coexistence of the two entities, there is a growing need for optimizing treatment in these patients.

Several postulated mechanisms underlying the increased concomitance of MPN and LPD have been suggested. Notably, coexistence of a B-cell clone has been observed in MPN patients. Indeed, Pajor et al. \[[@B17]\] have shown that 5% of MPN patients harbor a clonal B-cell population as demonstrated with clonal immunoglobulin gene rearrangements. In addition, a coexisting B-cell clone was detected in 16.3% of myelofibrosis patients in a different study, in line with previous findings. Interestingly, when treated with JAK inhibitors, this subgroup of patients was at an increased risk of developing B-cell neoplasms \[[@B18]\]. In our cases series, a patient treated with JAK2 inhibitor, indeed, developed MZL; however, it should be noted that this patient\'s exposure to anti-TNF (tumor necrosis factor) agents for her ankylosing spondylitis could have also contributed to her lymphoma \[[@B19]\]. It should also be noted that whether JAK2 inhibitors are associated with an increased risk of lymphomagenesis remains equivocal, as the observational studies by Pemmaraju et al. \[[@B20]\] and Rumi et al. \[[@B21]\] did not show an increased risk of lymphoma in patients treated with these agents compared to those alternatively treated.

There is growing evidence that abnormalities in certain genes can result either in myeloid or in lymphoid malignancies. This is particularly true for the *BCR/ABL1* fusion gene and the *PDGFRA*, *PDGFRB*, and *FGFR1* genes \[[@B22]\] as well as for *TET2* mutations, observed in MDS, CMML, and in B and mainly T LPDs \[[@B23]\], for *SF3B1* mutations, associated with both the MDS-RS phenotype and B-CLL \[[@B24], [@B25]\].

Whether the two concomitant diseases originate in the same or in two different clones is difficult to postulate in the everyday clinical setting. In cases where both myeloid and lymphoid cells harbor the JAK2 mutation, a common *JAK2 V617F*-mutated progenitor probably exists \[[@B9]\]. On the other hand, when the mutation is not detected in the B cells, two separate clones are present at the same time \[[@B7], [@B8]\]. A possible explanation could be that a milieu of genomic instability exists, leading to the acquisition of a *JAK2 V617F* mutation in one clone and the development of a separate B-cell clone in the same patient \[[@B26]\].

The inflammatory bone marrow microenvironment could be the cause of such instability. In support of this notion, it has been shown that in PMF, clonal cells produce inflammatory cytokines, which in turn promote remodeling of the microenvironment in the abnormal niche \[[@B27]\]. Furthermore, in vivo experiments have demonstrated that tissues characterized by chronic inflammation promote specific B-cell tumorigenesis by providing an environment where neoplastic B cells escape normal regulatory mechanisms \[[@B28]\]. These two observations could explain two main findings of our study: the high prevalence of PMF in keeping with that observed by Porpaczy et al. \[[@B18]\] as well as the high rate of precedence of the MPN over the LPD.

There are several limitations in this study. Importantly, no extrapolation of the incidence of concomitant MPN and LPD in the entire Greek population can be made as this study includes a population from a single institution. Moreover, because of the retrospective nature of this study, some information regarding patient history and initial presentation is missing. Finally, a thorough molecular testing for these patients could not be done due to practical difficulties; certainly, the results of such testing would have shed light on the clonal association of the two neoplasms in these patients.

In conclusion, we have presented a relatively large number of patients with MPN and a coexistent LPD. Various difficulties pertain to the diagnosis and management of these patients. More research is needed to elucidate the underlying mechanisms predisposing for both MPN and LPD coexistence.
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###### 

Patient characteristics and response to treatment.

  Case Number             1                  2                                  3                                 4                                 5                          6                                7                                 8                        9
  ----------------------- ------------------ ---------------------------------- --------------------------------- --------------------------------- -------------------------- -------------------------------- --------------------------------- ------------------------ ------------------
  DOB                     1942               1947                               1930                              1956                              1930                       1942                             1924                              1959                     1955
  Gender                  Male               Male                               Male                              Male                              Female                     Male                             Female                            Female                   Female
  Comorbidities           CAD, AH            AH, BPH                            CAD, peptic ulcer                 AH, NSCLC, abdominal aneurysm     Dementia, thyroid goiter   AH, thoracic aneurysm            Hypothyroidism, glaucoma          Ankylosing spondylitis   Nonsignificant
  MPN                     Pre-fibrotic PMF   PV                                 MDS/MPN-RS-T                      PMF                               Pre-fibrotic PMF           MDS/MPN-RS-T                     MDS/MPN-RS-T                      PMF                      Post-ET MF
  *JAK2 V617F*            Positive           Positive                           Negative                          Positive                          Positive                   Negative                         Negative                          Positive                 Positive
  MPN treatment           Observation        Hydroxycarba mide, bloodlettings   Epoetin alpha, RBC transfusions   Hydroxycarbamide, bloodlettings   Hydroxycarbamide           Epoetin alfa, RBC transfusions   Epoetin alpha, RBC transfusions   Ruxolitinib              Hydroxycarbamide
  Age at MPN              74                 67                                 84                                60                                85                         74                               85                                53                       59
  LPD                     MBL                B-CLL                              B-CLL                             MZL                               MM                         PBL                              B CLL                             Splenic MZL              LHCDD
  Age at LPD              74                 70                                 86                                50                                86                         76                               93                                57                       63
  LPD treatment           Observation        Obinutuzumab/Chlorambucil          Observation                       Splenectomy, Rituximab            Lenalidomide               Bortezomib-CHOP                  Obinutuzumab/Chlorambucil         RCOP                     VCD
  LPD treatment outcome   NA                 CR                                 NA                                PR                                Intolerance                CR                               Intolerance                       CR                       CR

DOB: Date of birth, MBL: Monoclonal B-cell lymphocytosis, MF: Myelofibrosis, B-CLL: B chronic lymphocytic leukemia, MM: Multiple myeloma, LHCDD: Light and heavy chain deposistion disease RBC: Red blood cell, MDS/MPN RS-T: Myelodysplastic syndromes/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis, CAD: Coronary artery disease, AH: Arterial hypertension, BPH: Benign prostate hyperplasia, NSCLC: NonSmall cell lung carcinoma, CR: Complete response, PR: partial response, MZL: Marginal zone lymphoma, PBL: Plasmablastic lymphoma, VCD: Bortezomib, cyclophosphamide, dexamethasone, RCOP: Rituximab cyclophosphamide vincristine prednisolone CHOP: Cyclophosphamide, doxorubicin, vincristine, prednisolone, NA: Nonapplicable.
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